FOXO1 and nasopharyngeal carcinoma: FOXO1 is generally accepted as a downstream regulator of AKT.[35] However, recent studies have shown that FOXO1 also acts as an upstream factor of AKT in gastric cancer and activates this pathway to mediate cisplatin resistance.[36] In this work, FOXO1 was shown to activate the AKT pathway, which was consistent with the findings reported by Zhao et al. in nasopharyngeal carcinoma.[37] FOXO1 target genes reportedly greatly differ in different cell types,[38] which may at least partially account for these discrepancies.